Telomir Pharmaceuticals Achieves Breakthrough in Silver-Ion Stabilization

MIAMI, FLORIDA / February 21, 2025 /

Telomir Pharmaceuticals, a leader in age-reversal science, has announced a groundbreaking achievement with its innovative compound Telomir-1. This development overcomes a longstanding challenge in silver-based medical applications by successfully capturing and stabilizing both Silver(I) and Silver(II) in a biologically compatible form.

Overcoming Silver(I) and Silver(II) Limitations

Silver has long been valued for its antimicrobial properties in medical treatments, particularly in wound care, burn treatment, and medical coatings. While Silver(I) compounds have strong antibacterial activity, Silver(II) offers enhanced healing potential due to its greater oxidative capacity and ability to penetrate biofilms.

The challenge lies in stabilizing Silver(II), which is highly reactive and degrades rapidly. Until now, attempts to stabilize Silver(II) in medical applications have faced numerous hurdles including toxicity and instability.

Telomir-1’s Unique Stabilization Mechanism

Telomir-1 is the first known biologically compatible carrier capable of stabilizing Silver(II) for medical use. This development could unlock a range of new applications, including advanced antimicrobial treatments, wound care solutions, and infection-resistant medical coatings.

Advantages of Silver(II) in Healing

Silver(II) has more potent antimicrobial action, displacing bacterial cell membranes, proteins, and DNA more aggressively than Silver(I). It also accelerates wound healing by stimulating fibroblast activity and scaring processes.

Additionally, Silver(II) reduces excessive inflammation, promotes the formation of new blood vessels, and supports tissue repair, making it a promising element in chronic wound management and medical device coatings.

Market Potential of Silver-Based Therapeutics

The market for silver-based medical treatments is rapidly growing. In 2024, the silver wound dressings segment was worth $1.03 billion, expected to reach $1.36 billion by 2030. The antimicrobial coatings market, which includes silver-infused medical devices and hospital surfaces, is poised to grow from $11.65 billion in 2024 to $33.7 billion by 2031, at a compound annual growth rate (CAGR) of 14.2%.

Expansion of Medical Applications

The potential to stabilize both Silver(I) and Silver(II) in controlled-release formulations may enable new and more effective treatments:

• Burn and wound care – Enhanced antimicrobial efficacy and accelerated healing could prevent infections in severe burns and open wounds.
• Chronic wound management – Improved therapies for conditions like diabetic ulcers and MRSA infections.
• Medical device coatings – Sustained antimicrobial protection for hospital surfaces, implants, and catheters, significantly reducing the risk of hospital-acquired infections.

Scientific Insight

“The ability to stabilize Silver(II) is a significant leap forward in medical chemistry,” said Dr. Itzchak Angel, Ph.D., Chief Scientific Advisor of Telomir. “Telomir-1’s achievement could transform topical antimicrobial treatments and enhance infection control, reshaping how silver-based medicine is used in modern healthcare.”

Dr. Alex Weisman, Ph.D. in Chemistry and Scientific Advisor at Telomir, emphasized that “Telomir-1’s ability to complex with Silver(II) provides an unprecedented solution, allowing us to harness the full potential of Silver(II) in a controlled and biologically safe manner.”

Future Developments

Telomir is advancing research and development to explore clinical applications of stabilized Silver(II) with Telomir-1, evaluating regulatory pathways to bring these innovations to market.

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage pharmaceutical company focused on developing Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen DNA’s protective telomere caps. Telomir aims to explore the potential of Telomir-1 through ongoing research in animals and eventual human studies.

Telomir-1 is currently in preclinical development and has not yet been tested in humans. The FDA has not approved Telomir-1 for any medical treatment at this stage.

Conclusion

Telomir Pharmaceuticals’ achievement with Telomir-1 represents a significant breakthrough in medical chemistry and antimicrobial treatments. By stabilizing Silver(II) in a biologically compatible form, Telomir-1 opens up a wide array of potential medical applications, from wound care to infection-resistant medical coatings. The future of silver-based medicine is poised for transformative changes.

Join the conversation on this exciting development and share your thoughts below! Don’t forget to subscribe to our newsletter for more updates on groundbreaking medical innovations.